Studies argue in favor of hydrogen sulfide (H2S) as the next potent therapeutic agent for neurodegenerative diseases. In present study, we investigated effect long term treatment with NaHS (as donor H2S) on induction and progress 6-hydroxydopamine (6-OHDA) -induced Parkinsonism rat. The 6-OHDA was injected into medial forebrain bundle right hemisphere by stereotaxic surgery. Behavioral tests tr...

Cortico-basal ganglia beta oscillations (13–30 Hz) are assumed to be involved in motor impairments Parkinson’s Disease (PD), especially bradykinesia and rigidity. Various studies have utilized the unilateral 6-hydroxydopamine (6-OHDA) rat PD model further investigate test novel treatments. However, a detailed behavioral electrophysiological characterization of model, including analyses popular ...

Oxidative stress caused by dopamine (DA) may play an important role in the pathogenesis of Parkinson's disease (PD). (+/-) Isoborneol is a monoterpenoid alcohol present in the essential oils of numerous medicinal plants and is a known antioxidant. In this study, we investigated the neuroprotective effect of isoborneol against 6-hydroxydopamine (6-OHDA)-induced cell death in human neuroblastoma ...

Background. Parkinson's disease (PD) is a progressive neurodegenerative disease that causes severe brain dopamine depletion. Disruption of iron metabolism may be involved in the PD progression. Objective. To test the protective effect of (-)-epigallocatechin-3-gallate (EGCG) against 6-hydroxydopamine- (6-OHDA-) induced neurotoxicity by regulating iron metabolism in N27 cells. Methods. Protectio...

The differential effects of dopaminergic drugs with different pharmacological profiles were investigated with respect to spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine (6-OHDA). Three marmosets received infusions of 6-OHDA (either 30 or 40 μg/side) into the bilateral dopamine-rich area running from the substantia nig...

We explored the impact of Nox-2 in modulating inflammatory-mediated microglial responses in the 6-hydroxydopamine (6-OHDA)-induced Parkinson's disease (PD) model. Nox1 and Nox2 gene expression were found to increase in striatum, whereas a marked increase of Nox2 expression was observed in substantia nigra (SN) of wild-type (wt) mice after PD induction. Gp91(phox-/-) 6-OHDA-lesioned mice exhibit...

Parkinson's disease (PD) is a progressive neurodegenerative disorder resulting in part from loss of nigrostriatal dopamine (DA) neurons. Treatments act only to relieve symptoms. It is therefore essential to develop treatments that slow or reverse the neurodegenerative process. Here, I explored exercise as a potential treatment against a 6-hydroxydopamine (6-OHDA) rat model. 6-OHDA causes select...

AIM To study the effect of group I metabotropic glutamate receptor (mGluR) ligands on 6-hydroxydopamine (6-OHDA)-induced death and glutamate release of PC12 cells. METHODS PC12 cells were exposed to 100 micromol/L of group I mGluR agonist (RS)-3,5-dihydroxy-phenylglycine (DHPG) or antagonist DL-2-amino-3-phosphonopropionic acid (DL-AP3) 1 h before addition of 6-OHDA 100 micromol/L. After incu...

Parkinson's disease (PD) is characterized by Lewy body and neurite pathology associated with dopamine terminal dysfunction. Clinically, it motor slowing, rigidity, tremor. Postural instability pain are also features. Physical exercise benefits PD patients - possibly promoting neuroplasticity including synaptic regeneration. In a parkinsonian rat model, we test the hypotheses that exercise: (a) ...

Glial cell line-derived neurotrophic factor (GDNF) injected intranigrally protects midbrain dopamine neurons against 6-hydroxydopamine (6-OHDA) toxicity. The timing between GDNF administration and exposure to 6-OHDA is critical in achieving optimal protection. When injected 6 hr before an intranigral injection of 6-OHDA, GDNF provides complete protection as measured by the number of surviving n...